


REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)



In re Application of

Application Number

07/310252

Filed

2-13-89

Art Unit

Examiner

48

Paper No.

39
#18
#44Assistant Commissioner for Patents
Washington, DC 20231

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:United States Patent Application Publication No. 6180370, page _____, line _____,

United States Patent Number _____, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Henry Dums
Signature

10-17-02

Date

Henry Dums
Typed or printed name

FOR PTO USE ONLY

Approved by: _____

(initials)

Unit: _____



US006180370B1

(12) **United States Patent**
Queen et al.(10) Patent No.: **US 6,180,370 B1**
(45) Date of Patent: ***Jan. 30, 2001**(54) **HUMANIZED IMMUNOGLOBULINS AND METHODS OF MAKING THE SAME**

(75) Inventors: Cary L. Queen, Los Altos; Harold E. Selick, Belmont, both of CA (US)

(73) Assignee: Protein Design Labs, Inc., Fremont, CA (US)

(*) Notice: Under 35 U.S.C. 154(b), the term of this patent shall be extended for 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 08/484,537

(22) Filed: Jun. 7, 1995

Related U.S. Application Data

(63) Continuation-in-part of application No. 07/634,278, filed on Dec. 19, 1990, now Pat. No. 5,530,101, which is a continuation-in-part of application No. 07/590,274, filed on Sep. 28, 1990, now abandoned, which is a continuation-in-part of application No. 07/310,252, filed on Feb. 13, 1989, now abandoned, which is a continuation-in-part of application No. 07/290,975, filed on Dec. 28, 1988, now abandoned.

(51) Int. Cl.⁷ A61K 39/395

(52) U.S. Cl. 435/69.6; 435/172.3; 435/328; 530/387.3; 530/388.2; 424/133.1; 424/143.1

(58) Field of Search 424/133.1, 143.1; 435/328, 69.6, 172.3; 530/387.3, 388.2

(56) **References Cited****U.S. PATENT DOCUMENTS**

4,578,335 3/1986 Urdal et al. 530/351
 4,816,397 3/1989 Boss et al. .
 4,816,565 3/1989 Honjo et al. 435/69.1
 4,816,567 3/1989 Cabilly et al. .
 4,845,198 7/1989 Urdal et al. 530/387
 4,867,973 9/1989 Goers et al. .
 5,198,359 3/1993 Taniguchi et al. .
 5,225,539 7/1993 Winter .
 5,530,101 * 6/1996 Queen et al. .
 5,585,089 * 12/1996 Queen et al. .
 5,693,761 * 12/1997 Queen et al. .
 5,693,762 * 12/1997 Queen et al. .

FOREIGN PATENT DOCUMENTS

0 120 694 10/1984 (EP) .
 2-0120 694 10/1984 (EP) .
 1-0125 023 11/1984 (EP) .
 0171496 2/1986 (EP) .
 0173494 3/1986 (EP) .
 0184187 6/1986 (EP) .
 0256654 7/1987 (EP) .
 0239400 9/1987 (EP) .
 1-0239 400 9/1987 (EP) .
 2-0239 400 9/1987 (EP) .
 0266663 6/1988 (EP) .
 1 0318 554 6/1989 (EP) .
 0 323 806 7/1989 (EP) .
 1-0323 806 7/1989 (EP) .
 0 0328 404 8/1989 (EP) .
 0 365 209 4/1990 (EP) .

2 0365 209 4/1990 (EP) .
 0 365 997 5/1990 (EP) .
 1-0368 684 5/1990 (EP) .
 2 0365 997 5/1990 (EP) .
 0 125 023 6/1991 (EP) .
 0456216 10/1991 (EP) .
 0460167 12/1991 (EP) .
 1-0519 596 12/1992 (EP) .
 1-0592 106 4/1994 (EP) .
 239400 8/1994 (EP) .
 2-0188 941 10/1987 (GB) .
 2188941 10/1987 (GB) .
 8928874 12/1989 (GB) .
 WO 86/05513 9/1986 (WO) .
 WO 87/02671 5/1987 (WO) .
 WO88/09344 12/1988 (WO) .
 WO 89/01783 3/1989 (WO) .
 WO89/09622 10/1989 (WO) .
 WO 90/07861 7/1990 (WO) .
 91/09967 7/1991 (WO) .
 WO 91/09966 7/1991 (WO) .
 WO 92/11018 7/1992 (WO) .
 WO 92/11383 7/1992 (WO) .
 WO92/11018 7/1992 (WO) .
 WO93/02191 2/1993 (WO) .
 WO 93006231 4/1993 (WO) .
 WO94/11509 5/1994 (WO) .
 WO 96/05229 2/1996 (WO) .

OTHER PUBLICATIONS

George et al Current Methods in Sequence Comparison and Analysis in Macromolecular Sequencing and Synthesis, 127-148, 1988.*

Barton et al Protein Sequencing Alignment and Database Screening Protein Structure Prediction. 31-63, 1996.*

(List continued on next page.)

* cited by examiner

Primary Examiner—Julie Burke

(74) Attorney, Agent, or Firm—Townsend and Townsend and Crew LLP

(57) ABSTRACT

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

30 Claims, 55 Drawing Sheets

OTHER PUBLICATIONS

- Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*", *Proc. Natl. Acad. Sci. U.S.A.* 85:5879-5883 (1988). in *Progress in Hematology XIV*, E. Brown, ed., Grune and Statton, New York (1986) p. 283.
- Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", *Nature* 321:522-525 (1986).
- Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," *Protein Engineering* 4:773-783 (1991).
- Kirkman et al., *Journal of Expt. Med.* vol. 162:358 Jul. 1985.
- Leonard et al., "The human receptor for T-cell growth factor," *J. Biol. Chem.* 260:1872-1880 (1985).
- Liu et al., "Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells", *Gene* 54:33-40 (1987).
- Maeda et al., "Construction of reshaped human antibodies with HIV-neutralizing activity", *Hum. Antibod. Hybrid.* 2:124-134 (1991).
- Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," *Proc. Natl. Acad. Sci.* 81:6851-6859 (1984).
- Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies," *Science* 229:1202-1207 (1985).
- Neuberger et al., "A hapten-specific chimeric IgE antibody with human physiological effector function," *Nature* 314:268-270 (1985).
- Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," *Proc. Natl. Acad. Sci. USA* 86:10029-10033 (1989).
- Riechmann et al., "Reshaping human antibodies for therapy", *Nature* 332:323-327 (1988).
- Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement," *Eur. J. Immunol.* 21: 2717-2725 (1991).
- Sahagan et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen", *J. Immunol.* 137:1066-1074 (1986).
- Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene," *J. Exp. Med.* 175:217-225 (1992).
- Sharon et al., "Expression of a $V_H C_K$ chimaeric protein in mouse myeloma cells", *Nature* 309:364-367 (1984).
- Shearman et al., "Construction, expression and characterization of humanized antibodies directed against the human α/β T cell receptor," *J. Immunol.* 147(12):4366-4373 (1991).
- Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", *Nature* 314:452-454 (1985).
- Tan et al., "A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells", *J. Immunol.* 135:3564-3567 (1985).
- Tempest et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo," *BioTechnology* 9:226-271 (1991).
- Uchiyama et al., "A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells," *J. Immunol.* 126:1393-1397 (1981).
- Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", *Science* 239:1534-1536 (1988).
- Vitteta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents," *Science* 238:1098-1104 (1987).
- Waldmann, T. A., "The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes," *Science* 232:727-732 (1986).
- Woodle et al., "Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression," *J. Immunol.* 148:2756-2763 (1992).
- Junghans et al., *Cancer Res.*, 50:1495-1502 (1990).
- Kupiec-Weglinski et al., *Proc. Natl. Acad. Sci.*, 83:2624 (1986).